2 results
Approved WMOCompleted
The primary objective of this study is to evaluate the effects of two types of AR treatment & placebo in counteracting AR*s effects on Cognition and Driving. Therefore, the effects of nasal provocation in AR patients on cognitive functions…
Approved WMORecruiting
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.